Introduction
Alpha1-antitrypsin (AAT) deficiency, one of the most common genetic diseases, is a well-known genetic cause of emphysema, liver disease, and other conditions (1) (2) (3) (4) (5) (6) related to the inheritance of two severe deficiency alleles at the locus encoding AAT, a protease inhibitor synthesized by the liver. The most frequent genetic variant responsible for severe AAT deficiency is the PiZ allele coding for an abnormal protein that forms polymers that accumulate within the endoplasmic reticulum of hepatocytes, thereby preventing the secretion of AAT in the bloodstream with ensuing low blood levels of AAT (2, 3, 7) . The main manifestations of AAT deficiency with the PiZZ phenotype are pulmonary emphysema, related to reduced protection from neutrophil elastase and presence of intrapulmonary polymers, and liver disease thought to be mediated by accumulation of polymerized PiZ protein within hepatocytes (8) . In contrast, the NullNull phenotype, which results in the absence of AAT production, is not associated with liver disease. The clinical expression of liver disease in PiZZ patients is highly variable, depending on the age of patients. In adults, in whom significant lung and liver disease are thought to rarely coexist in the same patient (2) , severe liver injury, including cirrhosis and hepatocellular carcinoma, may develop, but most patients remain asymptomatic (9) . Information about the prevalence and nature of liver disorders in PiZZ patients is well known in infants but scarce in adults (9) . In a recently published study, the prevalence of severe fibrosis or cirrhosis was 17.5% (10) . At our lung transplant center, in 2006, cirrhosis was diagnosed in an adult with PiZZ-related emphysema in the early postoperative period despite the absence of any suggestive clinical, laboratory, or liver imaging abnormalities detected on preoperative work-up. Liver decompensation developed after lung transplantation (LT). Since 2006, given the absence of validated noninvasive tests to assess liver fibrosis and in accordance with our reference hepatologists, our policy is to systematically perform a liver biopsy in all adult PiZZ-related emphysema patients who are candidates for LT. Our aim is to confidently detect patients with significant liver injury that could compromise the course of LT. Using this approach, we are thus able to estimate the prevalence and the nature of liver disease in PiZZ adult patients, at least in those with advanced emphysema being evaluated for LT.
The aim of the present study is to describe the results of our screening program.
Materials and Methods
The files of all the PiZ homozygotes patients being evaluated for LT at our center since July 2006 were reviewed retrospectively. All were adults, had PiZ-related advanced emphysema, and had agreed to be screened on a systematic basis by means of a percutaneous liver biopsy to exclude significant liver injury that could represent a contraindication for LT. The diagnosis of PiZZ deficiency was based on a combination of very low serum AAT level (< 11 lmol/L) and protein phenotyping and/or genotyping.
Data obtained at pretransplant evaluation
The following data were collected: age; gender; modalities of diagnosis of AAT deficiency (phenotype and/or genotype); administration of augmentation therapy; liver assessment data: risk factors of chronic liver disease (excessive alcohol consumption [defined by a mean regular consumption ≥ 20 g/day for a woman and ≥ 30 g/day for a man], presence of risk factors of nonalcoholic fatty liver disease [NAFLD] [overweight, systemic hypertension, dyslipidemia, data concerning abdominal perimeter being lacking in our patients], immune status against hepatitis C and hepatitis B viruses), results of liver function tests, presence of splenomegaly, hepatomegaly, abnormal contours of the liver or steatosis on abdominal ultrasonography; pulmonary assessment data: smoking status (never smoker or former smoker), requirement for long-term oxygen therapy, results of pulmonary function tests and blood gas analysis, presence and severity of pulmonary hypertension (mean pulmonary artery pressure value measured on right heart catheterization as a part of the pretransplant evaluation), and comorbidities.
Outcome data
The main outcomes were the following: proportion of patients undergoing LT, remaining on a waiting list, dying on waiting list, or in whom LT was considered contraindicated.
Besides collecting the above data, liver biopsy specimens were retrospectively reviewed by two experienced pathologists (DCH, LC) in a blinded fashion. The following items were analyzed: size of the biopsy; number of portal tracts; presence and degree of liver histological abnormalities (fibrosis, inflammation, steatosis, siderosis, and results of periodic acid-Schiff [PAS] staining after diastase digestion for identification of AAT globules). According to the Metavir score, fibrosis was graded from 0 to 4 and chronic lymphoid inflammation from 0 to 3. The degree of fibrosis was staged by the Ishak system on a 7-point scale (from 0, no fibrosis to 6, cirrhosis) (11) . Steatosis was quantified on Kleiner score from 0 to 3 and the number of patients filling the definition of NAFLD (12) (further categorized into nonalcoholic fatty liver [NAFL] and nonalcoholic steatohepatitis [NASH] ). AAT level in hepatocytes was graded semiquantitatively from 1 to 4 as described by Dawwas et al (10) . Severe chronic liver disease was diagnosed by the presence of severe septal fibrosis or cirrhosis on liver biopsy (Metavir score ≥3, and/or Ishak score≥4).
Statistical analysis
Baseline characteristics are reported as means (standard deviation [SD] ) and SD or number (%) and were compared by the Mann-Whitney U test and the Fisher exact test. p ≤ 0.05 was considered statistically significant. Correlations were sought using the Spearman correlation coefficient. Two multivariable linear models were built to assess the relationship between lifetime alcohol consumption and age, and the Metavir score and the Ishak score. Because of the small sample size, no attempt was made to include more variables in the multivariable models.
Results
From 2006 to 2014, 25 patients with AAT deficiencyrelated severe emphysema were referred to our center for consideration of LT. Two patients with SZ deficiency were excluded from the analysis because the risk of liver involvement is unclear in this setting (3). We included 23 PiZZ individuals (12 males). All had given their informed consent for ultrasonography-guided liver biopsy, which was performed without side effects with the exception of one case of mild spontaneously resolving pneumothorax. The flow chart of the 23 patients is shown in Figure 1 . During the study period, among the patients with PiZZ-associated liver cirrhosis referred to the liver transplant unit of our institution, none had severe lung disease that warranted LT (two patients had concomitant lung emphysema that was not severe enough to consider LT).
Pretransplant evaluation
The clinical characteristics of patients are shown in Table 1 . All patients except one had a history of smoking. There were no current smokers (a prerequisite before consideration for LT). Two patients had a history of excessive alcohol consumption, 10 used to consume alcohol occasionally, and 11 did not consume alcohol. Some patients presented features of metabolic syndrome: 6 had BMI ≥ 25 kg/m², but none had a BMI ≥ 30 kg/m²; 4 had a history of systemic hypertension; 1 had type 2 diabetes; and 6 had dyslipidemia (defined by triglycerides level >1.75 g/L for a man and >1.40 g/L for a woman; and/or low-density lipoprotein cholesterol level >1.60 g/L).
Current or previous comorbidities included venous thromboembolism (n = 3), osteoporosis (n = 2), bowel diseases (n = 3), history of prostatic cancer (n = 1), and Biermer disease (n = 1).
All patients had severe obstructive disease with marked hyperinflation ( Table 2 ). The % predicted mean forced expiratory volume in 1 s (FEV 1 ) was 24.4 (6.5); 19 patients (83%) had FEV 1 ≤ 30% predicted. In all, 20 patients (87%) received long-term oxygen therapy. On right heart catheterization, 13 showed mean pulmonary artery pressure ≥25 mmHg. Eight patients (35%) received AAT augmentation therapy and three underwent surgical lung volume reduction before being considered for LT.
The liver disease and ultrasonography findings are shown in Table 3 and Figure 1 . All patients were negative for hepatitis B and C. Synthetic liver function was well preserved in all patients. Only two had elevated alanine transaminase and aspartate aminotransferase levels. None had thrombocytopenia (defined as platelet count < 150 000/mm 3 ). The abnormalities revealed by abdominal ultrasonography were hepatomegaly (n = 3), abnormal contours of the liver (n = 1), splenomegaly (n = 1), and steatosis (n = 7).
The liver biopsy data are shown in Table 4 . All liver biopsies resulted in a confident histological diagnosis (median number of portal tracts analyzed: 19 ). The two pathologists showed good concordance in diagnosis.
Most patients (n = 19, 82%) showed PAS+ AAT globules in cytoplasm of periportal hepatocytes after diastase digestion ( Figure 2 ). AAT immunohistochemistry was performed in the four patients with no PAS globules found on biopsy. No hepatocytic AAT expression was
Normal synthetic function n=23
Elevated ALT and/or ALP and/or bilirubin n=3
Normal value of ALT, ALP, bilirubin n=20
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Normal liver ultrasound n=19
Abnormal liver ultrasound n=1
No severe Liver injury n=3
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Severe liver disease n=1
Severe liver disease n=1 
History of bowel disease, n (%) n = 3 (13%) SD, standard deviation. Home oxygen therapy, n (%) 20 (87%) AAT augmentation therapy, n (%) 8 (34.8%) Surgical lung volume reduction, n (%) 3 (13%)
The data are for the 23 patients unless indicated. COPD, chronic obstructive pulmonary disease; FEV 1, forced expiratory volume in 1 s; SD, standard deviation; RV, residual volume; TLC, total lung capacity; DLCO, diffusing capacity for carbon monoxide; AAT, alpha1-antitrypsin.
found after immunohistochemistry in any of these four patients. On the biopsied site, the accumulation of AAT was substantial in six patients (26%), scored 3 or 4; patchy in 13 (56%), scored 1 or 2; and absent in 4 (17%). In all, 20 patients (87%) showed chronic liver disease characterized by lymphoid inflammation and/or significant portal fibrosis on histology; the remaining 3 patients had no inflammation and no fibrosis but showed PAS+ AAT globules in periportal spaces (patchy, scored 2 or 1).
Chronic inflammation was found in 13 patients (56%), graded as minimal (n = 12) or moderate (n = 1), generally limited to scarce lymphocytes in portal tracts without lobar inflammation and without extensive piecemeal necrosis. Portal fibrosis was present in 19 patients (83%), graded as minimal in 17 patients, corresponding to nonseptal portal fibrosis.
When the patients were split according to the median Ishak score (median value=1), no statistical difference was found in the patient characteristics (Table 5) .
Two patients (8.7%) (patients 4 and 8) had septal fibrosis according to the Metavir and Ishak scores and met our definition of severe chronic liver disease. Patient 4, who had a history of excessive alcohol consumption, had cirrhosis (graded 4 and 5 according to Metavir and Ishak scores, respectively) without steatosis and had hepatitis but few AAT globules (score 1). The liver function findings were normal. He had no liver abnormality on abdominal ultrasonography. In this patient, the respective role of alcohol consumption and AAT deficiency are unknown. Patient 8, who had no history of excessive alcohol consumption or viral hepatitis, had at least septal fibrosis (graded 3 on both Metavir and Ishak scores). Liver The data are for the 23 patients unless indicated and are mean (standard deviation) unless indicated. AST, aspartate aminotransferase; ALT, alanine transaminase; ALP, alkaline phosphatase. function findings were normal, but on abdominal ultrasonography and hepatic magnetic resonance imaging, the liver appeared nodular with irregular contours, suggesting liver cirrhosis. No signs of portal hypertension were detected on ultrasonography. Hepatocellular carcinoma developed 6 months later, which was treated by radiofrequency ablation and chemoembolization.
Steatosis was present in 10 of the 23 patients (43%) but only 2 (patients 11 and 23) fulfilled the histologic criteria of NAFL and both showed clinical features of the metabolic syndrome. None had NASH. Individual data are shown in Table 6 . We found a strong correlation between steatosis measured on biopsy and on ultrasound (Spearman correlation coefficient = 0.61; p = 0.002). The mean (SD) score of steatosis on biopsy in patients without steatosis on ultrasound was 0.25 (0.44) compared to 1.43 (1.33) in patients with steatosis on echo (p value=0.005; Mann-Whitney U test).
In multivariable analysis, age and lifetime alcohol consumption were associated with Metavir score (R 2 =0.45) and Ishak score (R 2 =0.46), whereas the AAT score was not.
Patient Outcomes
Overall, 17 patients underwent LT. None showed manifestations compatible with a decompensation of severe chronic liver disease during the postoperative course. Among the six remaining patients, one died while on the waiting list (patient 7), two finally refused to be listed on the waiting list (patients 5 and 20), and the remaining three patients had a contraindication to LT because of severe liver disease (patients 4 and 8) or other comorbidities (patient 9).
Discussion
Liver biopsies from most patients (82%) showed AAT globules, the hallmark of the Z-type of AAT deficiency. AAT accumulation may be sparse and heterogeneous through the parenchyma. Therefore, negative detection of PAS globules in four patients of our series (17%) may be due to limited liver sampling by needle biopsy, or may indicate that a small proportion of patients had mild accumulation.
Liver disease is a well-known manifestation of AAT deficiency, which is not related to a proteolytic mechanism but rather considered to result from intrahepatocyte accumulation of pathologic polymerization of the variant AAT (2, (6) (7) (8) . Therefore, liver disease is mainly observed in patients with phenotypes characterized by intrahepatocyte polymerization. The two alleles best described to confer risk of liver disease are Z and M (malton), the PiZZ phenotype being the most frequently involved (6, 8) . In PiZZ homozygotes, the natural history of liver disease remains poorly understood. The available data for children are mainly based on prospective cohorts of PiZZ patients screened at birth and followed over time (13, 14) . In PiZZ adults, information on the prevalence of liver disease remains limited and is mainly based on retrospective cohorts. Such patients may exhibit chronic hepatitis, cirrhosis, or hepatocellular carcinoma. Severe liver disease is more frequently observed in adults than children, with a prevalence of approximately 15-20% in cohort studies (4, 15, 16) . Male gender, obesity, and age may be risk factors of progression to advanced liver disease in PiZZ adult patients (15) (16) (17) (18) , and the general belief is that significant lung and liver disease rarely coexist in the same patient (2).
A recently published study has brought an important contribution to the field. Dawwas et al assessed the prevalence and risk factors of severe liver disease in a cohort of 57 adults with PiZZ-related lung disease (10, 19) . The patients were screened prospectively for clinical, laboratory, and imaging evidence of severe liver disease. For cases with any abnormality suggestive of liver disease, where appropriate clinically, the patients underwent percutaneous liver biopsy. For the 24 patients who underwent liver biopsy, 10 (17.5% of the cohort) had evidence of severe fibrosis or cirrhosis. The authors also showed that the sensitivity of liver ultrasonography for detecting severe liver disease was 100%. They concluded that a combination of usual liver function tests, platelet count, and liver ultrasonography was an effective screening strategy. Our study of PiZZ adult patients, candidates for LT because of advanced emphysema, confirmed that severe liver disease may coexist with severe emphysema. Our observed rate of severe liver disease (<10%) was somewhat lower than that found by Dawwas et al (10) . Despite being prospective, the approach differed in the two studies. Performance of liver biopsy was based on preliminary screening in the Dawwas study and was systematic in our study, which allows for a more precise estimate of the prevalence of severe liver disease in this particular setting of adult patients with PiZZ-related emphysema.
The optimal modalities to detect PiZZ adult patients with severe liver disease need to be defined. The poor diagnostic value of liver function tests has been underlined (18) . According to the prospective study by Dawwas et al (10) , patients with PiZZ-related lung disease could be effectively screened by simple tests including liver function tests, platelet count, and liver ultrasonography with for the latter a sensitivity and negative predictive value of 100%. Interestingly, in the two patients of our study with severe liver disease, clinical and laboratory assessment did not detect any abnormalities and abdominal ultrasonography gave normal findings in one case and disclosed abnormal contours of the liver in the other. Furthermore, our patient in 2006 who led us to modify our approach and to systematically perform liver biopsy for LT candidates had Besides the abovementioned strength of our study, there are several limitations. First, the analysis concerned a small cohort, so our results should be considered with caution. In particular, out of 23 patients, we identified only 1 case of severe liver disease without any clinical, laboratory, and imaging abnormalities. Second, selection bias could have led to an underestimation of the true prevalence of severe liver disease. Even though we assessed all referred patients systematically, we cannot exclude that PiZZ emphysematous patients with known liver disease were not referred to our center because LT would have been contraindicated. Third, our results apply to only a particular subset of PiZZ adult patients: those 33-64 years old, with a smoking history in almost all cases, and candidates for LT for advanced emphysema. Our results may not apply to all adult PiZZ patients.
In conclusion, our data based on systematic liver biopsy indicate that the prevalence of advanced liver disease is <10% in adult patients with PiZZ-related pulmonary emphysema being evaluated for LT. However, most patients had some histologic involvement. Severe liver disease may be observed without any clinical, laboratory, or imaging abnormalities.
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